Levosimendan is a supportive treatment used across domains where additional symptomatic support is needed during severe, acute episodes of heart dysfunction. It is commonly used for the short-term treatment of acutely decompensated severe chronic heart failure when conventional therapy is not sufficient.

The therapeutic benefit is associated with providing circulatory assistance during periods of heightened physiological stress. It is relevant for managing symptom clusters that may become intense or disruptive, particularly those associated with significant symptomatic burden, such as low cardiac output and severe circulatory congestion. The medication helps address symptoms related to physical discomfort and systemic imbalance.

Common clinical scenarios where this treatment is used include stabilization during cardiogenic shock, use during the peri-operative phase of cardiac surgery, and in other situations where short-term symptomatic assistance is needed to assist with maintaining functional stability. It is commonly used for patients experiencing critical or unstable symptom patterns.

---

Quick Fact: Relief for Profound Dyspnea

Levosimendan supports patients during episodes of heightened discomfort by assisting the circulatory system, which may ease symptoms related to systemic imbalance and heightened physiological activity, such as severe breathlessness (dyspnea) and fatigue.

Who Can and Cannot Use Levosimendan?

Regulatory authorities strictly define the patient population eligible for Levosimendan use, primarily restricting it to adult patients (aged 18 and over). Use in children and adolescents is officially not recommended due to limited clinical experience.

---

Absolute Contraindications (Who Must Not Use)

Condition/Status	Eligibility Status
Severe Hepatic or Renal Impairment (CrCl < 30 ml/min)	Contraindicated
Severe Hypotension or Tachycardia	Contraindicated
History of Torsades de Pointes	Contraindicated
Significant Mechanical Obstruction affecting heart function	Contraindicated
Known Hypersensitivity to the medicine	Contraindicated

---

Conditional Use and Restrictions

Use of Levosimendan requires caution in patients with mild to moderate hepatic or renal impairment and necessitates extended monitoring. Before treatment begins, patients must have any coexisting hypokalaemia or severe hypovolaemia corrected. The medicine is conditionally used in pregnancy only if the maternal benefits outweigh fetal risks. Women who are breastfeeding should not use Levosimendan.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Levosimendan around two core risks: additive haemodynamic effects and altered metabolite exposure due to impaired clearance. Co-administration with medicinal products that prolong the QTc interval is strictly contraindicated, as this combination increases the documented risk of serious ventricular arrhythmia.

---

Interaction Classifications and Restrictions

Interaction Type	Interaction Outcome / Restriction
Pharmacodynamic Interaction	Caution is required when combining with other intravenous vasoactive medicinal products due to a documented risk of hypotension.
Pharmacodynamic Potentiation	Co-administration with Isosorbide Mononitrate resulted in a finding of significant potentiation of the orthostatic hypotensive response.
Exposure Risk (Population-Specific)	The medicine is contraindicated in patients with severe hepatic impairment or severe renal impairment (CrCl < 30 mL/min) due to the risk of prolonged exposure to active metabolites, leading to a pronounced haemodynamic effect.
No Pharmacokinetic Interaction	No significant pharmacokinetic interaction has been observed or documented with co-administration of Digoxin or beta-blocking agents.
Substance Interaction	The formulated concentrate contains a high concentration of anhydrous ethanol (785 mg/mL) as an excipient, which is a factor to consider during administration.

---

These restrictions define the boundaries for safe use as outlined by regulatory agencies. The primary constraint is managing the increased risk of blood pressure reduction when combined with other circulatory agents and preventing prolonged systemic exposure in patients with compromised organ function.

Calcium Sensitization and Myocardial Function

Levosimendan exerts its primary action by binding to cardiac troponin C (cTnC), a protein central to the contractile apparatus of heart muscle cells. This interaction increases the sensitivity of the myofilaments to the calcium already present in the cell. Functioning as a calcium sensitizer, the drug increases the force of heart contraction (positive inotropic effect) without increasing the concentration of intracellular calcium. This mechanism allows for increased mechanical power with a relative preservation of myocardial oxygen demand.

Vascular Modulation via Potassium Channels

Simultaneously, the medication acts as an opener of ATP-sensitive potassium channels (K ATP channels), particularly those located in the smooth muscle cells of blood vessels. Opening these channels leads to cell membrane hyperpolarization and subsequent smooth muscle relaxation, causing widespread vasodilation (widening of blood vessels). This mechanistic domain results in a significant reduction in both systemic and pulmonary vascular resistance.

Dual Systemic Effect

This dual action—enhanced myocardial contractility and reduced circulatory resistance—modulates the heart's function and the systemic vascular tone concurrently. The effect is an increased cardiac output (the volume of blood pumped per minute) resulting from the coordinated regulation of both the heart's pumping strength and the load against which it must work.

Levosimendan is supplied as a concentrate for solution for infusion (2.5 mg/ml) and is for Intravenous (IV) use only, administered in a strictly monitored hospital setting. The official instructions for its use follow a precise two-step process over a fixed duration.

Official Administration Protocol

Feature	Regulatory Instruction
Route	Intravenous infusion (peripheral or central line).
Preparation	Must be diluted prior to administration to a final concentration of 0.025 mg/ml or 0.05 mg/ml using solutions like 5% glucose.
Loading Dose	6 to 12 mu g/kg (micrograms per kilogram) administered over 10 minutes. The lower dose is recommended if the patient is receiving concurrent intravenous cardiovascular agents.
Continuous Infusion	Typically starts at 0.1 mu g/kg/min. The rate may be decreased to 0.05 mu g/kg/min or increased up to a maximum of 0.2 mu g/kg/min based on response.
Duration	The continuous infusion is generally maintained for 24 hours.

Population and Procedural Constraints

Before administration, conditions like severe hypovolaemia must be corrected. The patient's response is assessed within 30 to 60 minutes of starting or adjusting the dose. For older adults, no explicit dose adjustment is typically required, but use in children and adolescents under 18 years old is not recommended. Patients with mild to moderate renal or hepatic impairment require extended monitoring, which may last for at least 5 days following the end of the 24-hour infusion.

The clinical evaluation of levosimendan is based on evidence from controlled clinical trials, systematic reviews, and meta-analyses, all focusing on its use during periods of severe heart dysfunction. Research describes patterns observed in these studies.

Evidence for use in Acutely Decompensated Severe Heart Failure (ADHF)

This area has the most extensive research base, with studies exploring short-term symptom changes in adults with severe, acute heart failure. The main research design has been Randomized Controlled Trials (RCTs). These studies monitored hemodynamic parameters related to the heart’s function, examined how symptoms like shortness of breath and fatigue evolved, and included long-term follow-up for survival (30 to 180 days).

Research consistently reports on short-term hemodynamic function following administration. Studies also described changes in outcomes related to physical discomfort during the first few days of treatment. However, when monitoring for survival over the longer term, findings were inconsistent across the largest trials. The evidence is generally moderate regarding consistency for short-term effects, but inconsistent/low regarding long-term survival patterns.

Evidence in Other Critical Settings

Research has also explored levosimendan as a supportive agent during or immediately after major cardiac surgery (Peri-operative Cardiac Dysfunction). RCTs in this setting examined the occurrence of Low Cardiac Output Syndrome (LCOS) and the need for secondary circulatory support. Findings describe patterns observed in these studies, though reports were inconsistent when evaluating major combined outcomes like death and severe kidney failure.

For Cardiogenic Shock, evidence is generally limited, relying mainly on Observational Studies and Retrospective Analyses of critically ill patients. These studies tracked short-term survival rates and the ability to wean patients from mechanical support devices. Because of the critical nature of the condition, sample sizes were modest and data are still emerging, meaning the certainty of the findings remains low.

Research Gaps and Limitations

A main limitation is the inconsistency in findings regarding long-term survival across the largest RCTs. The research findings apply only to the populations studied and the specific conditions under which they were conducted. Furthermore, there is limited information for long-term outcomes and the durability of effects beyond the short-term treatment window. Research has also examined its use in children and adults with specific co-existing conditions, but data for certain groups remain insufficient.

Key Studies & References

1. Effect of Prophylactic Levosimendan on All-Cause Mortality in Pediatric Patients Undergoing Cardiac Surgery—An Updated Systematic Review and Meta-Analysis
2. The Perioperative Use of Levosimendan as a Means of Optimizing the Surgical Outcome in Patients with Severe Heart Insufficiency Undergoing Cardiac Surgery

Common questions about Levosimendan (FAQ)

---

Q: How is Levosimendan different from other inotropes like dobutamine?

Official information states that Levosimendan is classified as a calcium sensitizer and an inodilator. This dual action means it increases heart muscle contraction by increasing sensitivity to calcium and simultaneously relaxes blood vessels (vasodilation). Regulatory information notes this mechanism provides increased mechanical power with a relative preservation of myocardial oxygen demand.

---

Q: Does Levosimendan always cause a drop in blood pressure?

Official product information lists hypotension (low blood pressure) as a very common adverse reaction, meaning it occurs in 10% or more of patients. This risk is documented in regulatory safety tables, but the documents do not state that this effect is universal or happens to every patient who receives the medicine.

---

Q: How quickly can a patient expect to feel a change after the infusion starts?

The timing for observing the medicine's effect is used for clinical assessment and dose adjustment. Official instructions state that the patient's hemodynamic response to the medicine is to be evaluated by medical staff within 30 to 60 minutes of starting the infusion or making a dose adjustment.

---

Q: Who is responsible for monitoring the patient during Levosimendan infusion?

Official regulatory guidance states that Levosimendan must be administered in a strictly monitored hospital setting. This requires the infusion to be given in a facility where there are adequate monitoring facilities and expertise with the use of such potent cardiovascular agents are available.

---

Q: Is Levosimendan safe for elderly patients?

The official product information indicates that no explicit dose adjustment is typically required for older adults. However, regulatory documents specify that use in all patients requires careful and continuous haemodynamic monitoring.

---

Q: What patient information should be shared with the doctor before Levosimendan treatment?

Official regulatory documents list several conditions as contraindications (absolute restrictions) for using Levosimendan. These conditions include severe kidney or liver impairment, a history of a serious heart rhythm issue known as Torsades de Pointes, and known hypersensitivity to the medicine.

---

Q: Can a patient drive after receiving a Levosimendan infusion?

Official product information states that side effects like dizziness and hypotension (low blood pressure) may influence the ability to drive and use machines. Due to the nature of these effects, patients must be aware that their ability to drive may be impaired for a minimum of one hour after the infusion is complete.

---

Q: What type of monitoring is required while a patient is receiving Levosimendan?

Official regulatory documents specify that continuous monitoring of heart function is required while a patient receives the infusion. This monitoring includes continuous ECG and blood pressure monitoring. This close observation is documented to continue for at least three days, or longer for certain patient groups, after the infusion ends.

---

Q: Are there food or drink restrictions while receiving Levosimendan?

The prepared Levosimendan concentrate contains a high concentration of anhydrous ethanol (alcohol) as an inactive ingredient. While this is noted in regulatory documents, the official product information does not list specific restrictions on food or non-alcoholic drinks for the patient.

---

Q: Does Levosimendan interact with commonly prescribed blood thinners?

Official regulatory documents do not report any significant pharmacokinetic interaction with blood thinners (anticoagulants). However, a regulatory warning exists regarding co-administration with other intravenous vasoactive medicines due to a documented risk of hypotension (low blood pressure).

---

Q: What are the signs of a potential allergic reaction to Levosimendan?

Official regulatory documents state that Levosimendan is strictly contraindicated in patients with a known hypersensitivity to the active substance or its components. While the product label identifies this risk, the official adverse reaction tables do not detail the specific symptoms or signs of a potential allergic reaction.

---

Q: Is it possible to receive Levosimendan treatment more than once?

The standard regulatory protocol for Levosimendan describes a single 24-hour infusion. Official product information notes that clinical experience with repeated administration of the medicine is limited.

---

Q: Is Levosimendan approved for use in the United States?

As of the current regulatory documents, Levosimendan is approved and used in over 60 countries worldwide, but it is not approved for marketing in the United States or Canada for its use in acutely decompensated heart failure.

---

Q: Is Levosimendan used in countries other than those in Europe?

Yes. Official regulatory records confirm that the medicine is approved and used in over 60 countries worldwide, which includes jurisdictions outside of Europe.

---

Q: How long has Levosimendan been available on the market internationally?

According to regulatory history, Levosimendan was first approved in Sweden in 2000 for the short-term treatment of acutely decompensated severe chronic heart failure. Since then, it has been authorized in many countries for the short-term treatment of severe acute heart failure.

The storage and disposal of Levosimendan concentrate for infusion are strictly regulated to maintain product quality.

Storage Requirements

Item	Official Regulatory Condition
Concentrate Storage	Store in a refrigerator (2 °C to 8 °C). Do not freeze [1.1, 1.2, 1.6].
Appearance	The concentrate may turn to a darker orange color during storage, which does not indicate a loss of potency [1.2, 1.6].
Stability After Dilution	Chemical and physical stability is demonstrated for 24 hours at both 2 °C to 8 °C and 25 °C [1.2, 3.1].
Safety	Keep this medicine out of the sight and reach of children [1.2].

Disposal Instructions

Levosimendan is supplied in a single-use vial. Any remaining contents of the opened medicinal product must be discarded immediately [3.1].

For environmental protection, the product must not be thrown away via wastewater or household waste [3.1]. Individuals are instructed to ask a pharmacist how to properly dispose of unused medicines [3.1].